Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Willett, W. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Willett, W. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences, Vol 52, 127-146, Copyright © 1999 by Society of Toxicology

ARTICLES

Dietary fat and breast cancer

WC Willett
Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02130, USA. dosulliv@sph.harvard.edu

Good reasons exist to reduce intake of animal and partially hydrogenated fat. Existing data, however, provide little support for the hypothesis that reduction in dietary fat composition, even to 20% of energy during adulthood, will lead to a substantial reduction in breast cancer in Western cultures. Some evidence suggests that substituting monounsaturated fat for other sources of energy may even reduce risk of breast cancer; this deserves further examination. Also, the avoidance of weight gain during adulthood has many benefits, which are likely to include an important reduction in risk of postmenopausal breast cancer.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
J. A. Menendez, L. Vellon, R. Colomer, and R. Lupu
Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (HerceptinTM) in breast cancer cells with Her-2/neu oncogene amplification
Ann. Onc., March 1, 2005; 16(3): 359 - 371.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.